Fortress Biotech Subsidiary Closes $205 Million Priority Review Voucher Sale

Key Facts

1Cyprium Therapeutics, a subsidiary of Fortress Biotech, closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV).

2The sale generated gross proceeds of $205 million.

3Management described the transaction as transformational for the corporate structure of both Cyprium and Fortress.

Cyprium Therapeutics, a subsidiary of Fortress Biotech (FBIO), has successfully finalized the sale of its Rare Pediatric Disease Priority Review Voucher (PRV). The transaction generated gross proceeds of $205 million, marking a significant liquidity event for the company. Management characterized the deal as transformational for the corporate structures of both Cyprium and Fortress. This substantial cash infusion provides the biotechnology firm with non-dilutive capital to support its ongoing operations and strategic initiatives. The sale highlights the intrinsic value of regulatory assets in the biotech sector and strengthens the parent company's balance sheet. Investors view the move as a positive development that enhances financial flexibility without equity dilution.